Loading data for IRD — first visit, this takes a few seconds.

알림

Opus Genetics Inc. (IRD)

NasdaqCM: IRD · 실시간 가격 · USD

3.65

+0.04 (1.11%)

종가 기준: Aug 17, 2026, 8:00 PM

1.11% (1D)

데이터 없음

매수호가	2.68
시가총액	303.66M
매출 (ttm)	9.86M
순이익 (ttm)	-107.61M
베타	0.58
EPS (ttm)	-1.31
P/E (ttm)	n/a
선행 P/E	-5.15
P/B (ttm)	-23.25
P/S (ttm)	30.81
Earnings Date	Nov 11, 2026

매도호가	4.63
거래량	603,428
평균 거래량 (20일)	952,954
시가	3.60
전일 종가	3.61
일중 범위	3.55 - 3.75
52주 범위	1.10 - 5.81
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

IRD 소개

Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease. The compa...

[더 보기]

산업 Biotechnology

섹터 Healthcare

IPO 일자 Nov 10, 2005

직원 수 27

상장 거래소 NasdaqCM

티커 IRD

웹사이트 https://opusgtx.com

전체 기업 정보

재무 실적

2025년 Opus Genetics의 매출은 14.2M로, 전년 10.99M 대비 29.15% 증가했습니다. 순이익은 -49.59M로, -13.8% 감소했습니다.

재무제표

어닝 서프라이즈

Opus Genetics가 Aug 6, 2026에 분기 실적을 발표했습니다:

매출 $755K 예상치 하회 $0, 및 -73.80% 전년 대비 감소.

EPS -0.08 예상치 상회 0.08, 및 33.33% 전년 대비 성장.

다음 실적 발표

Opus Genetics Inc.의 실적 발표 예정일은 Nov 11, 2026, 장 시작 전입니다.
애널리스트 예상 매출은 ... 업그레이드

뉴스

1주 전 · Zacks

Opus Genetics, Inc. (IRD) Reports Q2 Loss, Lags Revenue Estimates

Opus Genetics, Inc. (IRD) delivered earnings and revenue surprises of +6.67% and -75.03%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

1개월 전 · Insider Monkey

RBC Capital Bullish On Opus Genetics (IRD) Amid Limited Competition And De-Risked Setup

Opus Genetics, Inc. (NASDAQ:IRD), backed by significant analyst-implied upside, ranks among the overlooked penny stocks to buy right now. A bullish new analyst call and a broadening gene therapy pipel...

2개월 전 · Insider Monkey

Guggenheim Initiates Coverage Of Opus Genetics (IRD) With “Buy” Rating And $16 Price Target

While Opus Genetics, Inc. (NASDAQ:IRD) has gained 100.50% year-to-date, analysts continue to see 148.10% upside, helping it secure a spot on our list of hot biotech stocks under $5 to buy. Fresh cover...

2개월 전 · MarketBeat

Opus Genetics Touts Retinal Gene Therapy Pipeline, September BEST1 Data Catalyst

Opus Genetics (NASDAQ:IRD) is advancing a portfolio of gene therapies for inherited retinal diseases, with two programs already in the clinic and three more expected to enter clinical testing within t...

3개월 전 · Zacks

Opus Genetics, Inc. (IRD) Reports Q1 Loss, Misses Revenue Estimates

Opus Genetics, Inc. (IRD) delivered earnings and revenue surprises of -374.68% and -23.18%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

2 페이지 중 1

Opus Genetics Inc. (IRD)